Nab-Sirolimus + Pazopanib for Soft Tissue Sarcoma
Trial Summary
What is the purpose of this trial?
This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Research Team
Lee Cranmer
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
Adults (18+) with advanced nonadipocytic soft tissue sarcomas not suitable for surgery or curative treatments, who haven't had more than four systemic therapies. Participants must have manageable cholesterol and triglyceride levels, normal heart function, adequate blood counts, and no major organ dysfunction. They should not be pregnant or breastfeeding and must agree to use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive nab-sirolimus intravenously on days 1 and 8 or day 1 only and pazopanib hydrochloride orally daily on days 1-21. Cycles repeat every 21 days until disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion at 30 days, then every 12 weeks.
Treatment Details
Interventions
- Pazopanib hydrochloride
- Sirolimus Albumin-bound Nanoparticles
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Aadi Bioscience, Inc.
Industry Sponsor